Cytek Biosciences shares rise 11.09% premarket after TIME’s 2026 Growth Leaders recognition boosts momentum.

Cytek Biosciences surged 11.09% in premarket trading following its inclusion in TIME’s 2026 list of America’s Growth Leaders, a recognition that highlights its momentum in cell analysis technology. The stock has gained 39% in the last month and 35% over the past quarter amid growing optimism around its advanced flow cytometry solutions for personalized medicine and immunotherapy. While Wall Street’s fair value estimate of $5.13 suggests the stock may be overvalued, the immediate premarket rally reflects renewed investor confidence driven by the high-profile award and broader industry tailwinds in healthcare R&D. Analysts note that sustained growth will depend on executing against aggressive top-line forecasts and navigating competitive pressures, but the recent recognition has amplified near-term bullish sentiment.